(Q37822721)

23 August 2017

1 reference

title

Denosumab: a review of its use in the treatment of postmenopausal osteoporosis (English)

1 reference

23 August 2017

0 references

Marit D Moen

1

1 reference

23 August 2017

Susan J Keam

series ordinal

2

1 reference

23 August 2017

language of work or name

1 reference

1 January 2011

1 reference

23 August 2017

1 reference

23 August 2017

28

1 reference

23 August 2017

1

1 reference

23 August 2017

63-82

1 reference

https://scigraph.springernature.com/pub.10.2165/11203300-000000000-00000

23 August 2017

0 references

cites work

Pharmacologic treatment of low bone density or osteoporosis to prevent fractures: a clinical practice guideline from the American College of Physicians

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F11203300-000000000-00000

Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025.

21 January 2018

1 reference

12 December 2020

Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate.

1 reference

12 December 2020

Do RANKL inhibitors (denosumab) affect inflammation and immunity?

1 reference

12 December 2020

Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone mass

1 reference

12 December 2020

What is the best balance of benefits and risks among anti-resorptive therapies for postmenopausal osteoporosis?

1 reference

12 December 2020

Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis

1 reference

12 December 2020

Comparison of effects of the bisphosphonate alendronate versus the RANKL inhibitor denosumab on murine fracture healing.

1 reference

12 December 2020

Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial

1 reference

12 December 2020

Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial

1 reference

12 December 2020

Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate

1 reference

12 December 2020

Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy.

1 reference

12 December 2020

Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease.

1 reference

12 December 2020

Denosumab improves density and strength parameters as measured by QCT of the radius in postmenopausal women with low bone mineral density

1 reference

12 December 2020

Effects of denosumab on bone mineral density and bone turnover in postmenopausal women

1 reference

12 December 2020

Managing osteoporosis: challenges and strategies

1 reference

12 December 2020

Treatment of osteoporosis with denosumab

1 reference

12 December 2020

Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL.

1 reference

12 December 2020

Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies.

1 reference

12 December 2020

Requirements for DXA for the management of osteoporosis in Europe

1 reference

12 December 2020

A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women

1 reference

12 December 2020

Comment on: Cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis

1 reference

12 December 2020

European guidance for the diagnosis and management of osteoporosis in postmenopausal women

1 reference

12 December 2020

Denosumab in postmenopausal women with low bone mineral density

1 reference

12 December 2020

Denosumab for prevention of fractures in postmenopausal women with osteoporosis

1 reference

12 December 2020

Potential cost-effectiveness of denosumab for the treatment of postmenopausal osteoporotic women

1 reference

12 December 2020

Two-Year Treatment With Denosumab (AMG 162) in a Randomized Phase 2 Study of Postmenopausal Women With Low BMD

1 reference

12 December 2020

Decreased bone remodeling and porosity are associated with improved bone strength in ovariectomized cynomolgus monkeys treated with denosumab, a fully human RANKL antibody

1 reference

12 December 2020

Adherence to osteoporosis treatments: room for improvement

1 reference

12 December 2020

1 reference

12 December 2020

10.2165/11203300-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

23 August 2017

0 references

1 reference